
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a drug called IMCgp100 for melanoma that cannot be removed with surgery, or has spread to other parts of the body.
Doctors often treat melanoma with surgery. But sometimes it cannot be completely removed or has spread to other parts of the body. Researchers are looking for new treatments to help people in this situation.
In this trial, they are looking at a new drug called IMCgp100 which is a type of . It targets melanoma cells and helps the immune system to find and attack them. This is the first time the drug has been tested in people.
The aims of the study are to
You can enter this trial if you
You cannot enter this trial if you
This is trial is in 2 parts.
In part 1, doctors look for the highest safe dose of IMCgp100. The first patients taking part have a very low dose. If they don't have any serious side effects, the next few patients have a higher dose. And so on, until the researchers find the highest safe dose. This is called a dose escalation study.
You can have IMCgp100 in 2 different ways. Some people have IMCgp100 once a week for 8 weeks. Each period of 8 weeks is called a cycle of treatment.
Some people have IMCgp100 on 4 consecutive days. Then 3 weeks later, they have it for another 4 days. For them, this 6 week period is a cycle of treatment.
If you don't have bad side effects, you may be able to carry on having cycles of treatment for up to 6 or 7 months.
You have IMCgp100 through a drip into a vein. It can take up to 30 minutes each time.
In part 2, the researchers want to learn more about how well IMCgp100 works. Some people will have weekly IMCgp100. Some people will have daily IMCgp100. You have the highest safe dose for that way of having treatment that was found in the first part of the trial.
Whether you have weekly or daily doses of IMCgp100 will depend on when you join the trial. Your doctor will explain this to you.
You see the trial doctors and have some tests before you start treatment. The tests include
Before your first dose of IMCgp100, the study team will photograph any areas of melanoma on your skin. And they may ask your permission to take a .
If you have weekly IMCgp100, you will need to stay in hospital for 24 hours after the first dose.
If you have daily doses of IMCgp100, you will need to stay in hospital for the first 4 days.
You have a number of tests and scans throughout the treatment including blood tests, ECGs, skin photography and biopsies. You also have eye tests and hearing tests. Some people in part 2 of the trial will be asked to have a . This is so the researchers can discover more about how IMCgp100 works in the body.
When you finish treatment, the study team will continue to check how you are every few months.
This is the first time IMCgp100 has been tested in people and there may be side effects we don’t know about yet. A small number of people have now had IMCgp100 and the side effects seen have included
IMCgp100 may also cause inflammation of the eye or ear, which can cause changes to your vision and problems with your hearing or balance.It is possible you could have a more severe allergic reaction.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Mark Middleton
Experimental Cancer Medicine Centre (ECMC)
Immunocore
Freephone 0808 800 4040
Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.